Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Susumu Noguchi; Atsushi Okamoto; Jun Nohara; Manabu Ishitoko; Toshiki Watanabe; Takaya Nakamura

doi:10.1002/rcr2.1366

Effective management of lung spindle cell carcinoma with ipilimumab, nivolumab, carboplatin, and paclitaxel, demonstrating efficacy in brain metastases treatment

Respirol Case Rep. 2024 May 7;12(5):e01366. doi: 10.1002/rcr2.1366. eCollection 2024 May.

Authors

Susumu Noguchi¹, Atsushi Okamoto¹, Jun Nohara¹, Manabu Ishitoko¹, Toshiki Watanabe¹, Takaya Nakamura¹

Affiliation

¹ Respiratory Medicine Shiga General Hospital Moriyama Japan.

Abstract

A 76-year-old woman with cT1bN2M1b stage IVA spindle cell carcinoma of the right lower lobe of the lung, no driver gene mutation, and programmed death ligand 1 < 1%, was started on ipilimumab+nivolumab+carboplatin+paclitaxel. After two courses, the patient initiated maintenance therapy with ipilimumab+nivolumab. New multiple brain metastases were observed during treatment but resolved with continued treatment. We report a unique case of spindle cell carcinoma treated with ipilimumab+nivolumab+carboplatin+paclitaxel that resulted in long-term response and resolution of new brain metastasis.

Keywords: brain metastasis; ipilimumab; lung cancer; nivolumab; spindle cell carcinoma.

Publication types

Case Reports